Skip to main content
. 2018 Jan 31;9(36):24304–24319. doi: 10.18632/oncotarget.24368

Figure 3. Ruxolitinib enhanced the anti-tumor activity of chemotherapy agents in OVCAR-8 human ovarian cancer cells.

Figure 3

OVCAR-8 cells were treated with ruxolitinib either alone or together with chemotherapy agents, paclitaxel (A), carboplatin (B), cisplatin (C), doxorubicin (D), and topotecan (E), at various concentrations in a fixed molar ratio. Cell viability was determined 72 h later.